Analysts Offer Predictions for Immunic Q3 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Analysts at Brookline Capital Markets increased their Q3 2026 EPS estimates for shares of Immunic in a research report issued on Wednesday, August 12th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will post earnings per share of ($0.84) for the quarter, up from their previous forecast of ($1.07). The consensus estimate for Immunic’s current full-year earnings is ($3.93) per share. Brookline Capital Markets also issued estimates for Immunic’s Q4 2026 earnings at ($1.16) EPS and FY2026 earnings at ($3.86) EPS.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.36.

IMUX has been the topic of several other reports. Wall Street Zen upgraded Immunic from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright restated a “buy” rating and issued a $22.00 price objective (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Wedbush assumed coverage on shares of Immunic in a research note on Monday. They issued an “outperform” rating and a $45.00 price objective for the company. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. Finally, Roth Capital reissued a “buy” rating and set a $19.00 price objective on shares of Immunic in a report on Thursday, May 14th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $47.25.

Immunic Price Performance

Shares of IMUX stock opened at $16.03 on Monday. The company has a market capitalization of $218.65 million, a P/E ratio of -3.66 and a beta of 1.41. The company’s 50-day simple moving average is $14.53 and its two-hundred day simple moving average is $12.16. Immunic has a one year low of $5.06 and a one year high of $16.86.

Institutional Trading of Immunic

A number of institutional investors have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp purchased a new stake in Immunic during the 1st quarter worth approximately $187,000. Avidity Partners Management LP raised its holdings in shares of Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after buying an additional 2,000,000 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Immunic in the first quarter worth $1,020,000. XTX Topco Ltd acquired a new stake in shares of Immunic during the fourth quarter worth $120,000. Finally, Virtu Financial LLC acquired a new stake in shares of Immunic during the third quarter worth $99,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.